Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial
Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S1473309926004925?dgcid=rss_sd_all
Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S1473309926004925?dgcid=rss_sd_all
“Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial.” The Lancet Infectious Diseases.
@article{article68604,
title = {Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S1473309926004925?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...